Walleye Capital LLC Purchases Shares of 142,904 Ralliant Corporation $RAL

Walleye Capital LLC acquired a new position in shares of Ralliant Corporation (NYSE:RALFree Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 142,904 shares of the company’s stock, valued at approximately $10,522,000. Walleye Capital LLC owned about 0.13% of Ralliant at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of RAL. Danske Bank A S acquired a new stake in shares of Ralliant in the fourth quarter valued at about $25,000. Allworth Financial LP grew its stake in Ralliant by 134.4% in the fourth quarter. Allworth Financial LP now owns 511 shares of the company’s stock valued at $26,000 after purchasing an additional 293 shares in the last quarter. Palisade Asset Management LLC acquired a new position in shares of Ralliant during the 3rd quarter worth approximately $26,000. BOKF NA acquired a new position in shares of Ralliant during the 3rd quarter worth approximately $29,000. Finally, Wilmington Savings Fund Society FSB bought a new stake in shares of Ralliant during the 3rd quarter worth approximately $30,000.

Ralliant Trading Up 1.3%

RAL stock opened at $72.34 on Friday. Ralliant Corporation has a one year low of $37.27 and a one year high of $75.41. The stock has a market cap of $8.00 billion, a price-to-earnings ratio of -6.67, a price-to-earnings-growth ratio of 2.65 and a beta of 1.60. The company has a fifty day moving average price of $68.60 and a two-hundred day moving average price of $55.44. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.52 and a quick ratio of 1.00.

Ralliant (NYSE:RALGet Free Report) last issued its quarterly earnings data on Thursday, July 30th. The company reported $0.68 earnings per share for the quarter, beating the consensus estimate of $0.63 by $0.05. The company had revenue of $567.80 million for the quarter. Ralliant had a negative net margin of 56.38% and a positive return on equity of 14.97%. Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. Equities analysts anticipate that Ralliant Corporation will post 2.87 EPS for the current year.

Ralliant Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 23rd. Shareholders of record on Tuesday, September 8th will be issued a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 8th. Ralliant’s dividend payout ratio is currently -1.84%.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on RAL shares. BMO Capital Markets began coverage on Ralliant in a report on Monday, July 20th. They issued a “market perform” rating and a $78.00 price objective for the company. TD Cowen upped their price target on shares of Ralliant from $70.00 to $80.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Truist Financial reiterated a “buy” rating and issued a $82.00 price target (up from $68.00) on shares of Ralliant in a research note on Friday, July 31st. Weiss Ratings reiterated a “sell (d)” rating on shares of Ralliant in a report on Friday, July 31st. Finally, Royal Bank Of Canada upped their price objective on Ralliant from $71.00 to $73.00 and gave the company a “sector perform” rating in a research note on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $75.70.

Check Out Our Latest Research Report on Ralliant

About Ralliant

(Free Report)

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.

Featured Stories

Want to see what other hedge funds are holding RAL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ralliant Corporation (NYSE:RALFree Report).

Institutional Ownership by Quarter for Ralliant (NYSE:RAL)

Receive News & Ratings for Ralliant Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ralliant and related companies with MarketBeat.com's FREE daily email newsletter.